Nevertheless,
Snmmi launches platform powered ai:
The Society of Nuclear Medicine. Consequently, Molecular Imaging (SNMMI) is proud to announce the launch of the revolutionary platform on radiopharmaceutical trials, a revolutionary platform powered by AI, designed to help researchers, clinicians and patients instantly discover radiopharmaceutical clinical trials that meet their specific needs. Furthermore, This initiative represents a concrete step towards SNMMI’s objective to ensure patient access to nuclear medicine procedures that change. Moreover, their lives.
Developed by Ancora.ai. Consequently, hosted on the SNMMI website, the trial spray is designed to eliminate obstacles to the participation of clinical trials by offering a rationalized and friendly experience for doctors, patients and researchers. Meanwhile, The platform uses data on real-time global trials updated every 24 hours of clinicals.gov and three additional international registers. Nevertheless, No personal information is stored or sold.
Clinical snmmi launches platform powered ai trials are essential for the development of new radiopharmaceuticals. which have the potential to diagnose, treat and, in some cases, to cure cancer and other diseases. According to data from the National Institutes of Health. 84% of patients are planning to participate in a clinical trial if they were suggested by their doctor, but only 3% to 5% of patients with eligible adult cancer are actually. The trial spray aims to help fill this gap.
Patients start by selecting their condition and postal code. The test researcher then guides them through specific questions on the stage of the disease. previous treatment and other key factors, returning a tailor -made test list for which they can be eligible. Each result includes the force of correspondence with the test criteria. the distance from the test site of their location.
Doctors use the same interface to match patients with relevant trials, helping to snmmi launches platform powered ai identify appropriate opportunities quickly and precisely.
Researchers can look for thousands of radiopharmaceutical trials worldwide using specific parameters such as the trial phase. the type of radionuclide and the target. Additionally, The function of fast graphics in real time provides detailed ventilation of the types of tests. locations, sponsors and other criteria.
The global radiopharmaceutical trial researcher is a powerful example of how AI can be used to make nuclear medicine. more accessible to patients. With this tool, patients and their reference suppliers have vital care at hand. The global radiopharmaceutical trial researcher is available on www.snmmi.org/trialfinder.
Snmmi launches platform powered ai
Further reading: What is the “Brain Freeze”, this intense migraine that occurs when you eat an ice cream? – Eating this cheap food once a week would half the risk of suffering from Alzheimer’s disease – Italy: already nine dead since the start of the year because of the Western Nile Virus – A 15 -year study reveals which diets best protect your brain and your heart later in life – On four non -antibiotic drugs linked to an intestinal flora imbalance | Intestinal microbiome.